Bluesky Facebook Reddit Email

Tumor-suppressing protein may be novel target in PAH therapy

05.19.19 | American Thoracic Society

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.


ATS 2019, Dallas, TX -- In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH), according to research presented at ATS 2019. Researchers found that a deficiency of this protein produced dysfunctional molecules unable to support cell structure and function, resulted in thickening of pulmonary blood vessels and led to PAH.

###

Session: A97 Station to Station: Unraveling the Molecular Pathogenesis of PAH
Abstract Presentation Time: Sunday, May 19, 2:45 p.m. CT
Location: Room C147, 148 and154 (Level 1), Kay Bailey Hutchison Convention Center Dallas

VIEW ABSTRACT

CONTACT FOR MEDIA

Yuanjun Shen, PhD
sheny@pitt.edu

Keywords

Contact Information

How to Cite This Article

APA:
American Thoracic Society. (2019, May 19). Tumor-suppressing protein may be novel target in PAH therapy. Brightsurf News. https://www.brightsurf.com/news/8XGW04Y1/tumor-suppressing-protein-may-be-novel-target-in-pah-therapy.html
MLA:
"Tumor-suppressing protein may be novel target in PAH therapy." Brightsurf News, May. 19 2019, https://www.brightsurf.com/news/8XGW04Y1/tumor-suppressing-protein-may-be-novel-target-in-pah-therapy.html.